Mirapexin (Pramipexole Dihydrochloride Monohydrate)

Pramipexole works by selectively stimulating dopamine D2 and D3 receptors in the brain. This activation mimics dopamine, enhancing dopaminergic neurotransmission in pathways that control movement and sensory perception, which alleviates the motor and sensory symptoms associated with Parkinson's disease and restless legs syndrome.

The dose of Mirapexin is individualized and set by the prescribing healthcare professional based on the patient’s condition, response, and tolerability. Dosage adjustments may be required for renal function, age, or concomitant medications, and should always follow the prescriber’s instructions.

Safety data for pramipexole in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To order Mirapexin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirapexin (pramipexole) is a dopamine agonist, whereas levodopa is a dopamine precursor. Pramipexole can be used as monotherapy in early disease or as an adjunct to levodopa, often providing smoother symptom control with a lower risk of motor fluctuations, but it may have a higher incidence of impulse‑control disorders.

Mirapexin should be stored at ambient temperature, below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, excessive heat and direct light to maintain potency throughout the shelf life.

Mirapexin is taken orally, usually with or without food, as directed by the prescriber. Tablets are swallowed whole with a glass of water. The dosing schedule may start with a low dose that is gradually increased to the therapeutic level based on clinical response.

Serious risks include hallucinations, impulse‑control disorders (such as compulsive gambling or shopping), severe hypotension, sudden onset of sleep, and rare allergic reactions. Patients should be monitored for these events, especially during dose titration or when combined with other central nervous system agents.

Mirapexin is contraindicated in patients with known hypersensitivity to pramipexole or any of its excipients. Caution is advised in individuals with severe renal impairment, uncontrolled psychiatric illness, or those taking monoamine oxidase‑B inhibitors, as the combination may increase the risk of adverse effects.